IRADIMED CORPORATION to Hold 2018 Second Quarter Financial Results Conference Call on July 31st
July 16 2018 - 7:00AM
IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the
Company will release its 2018 second quarter financial results
before the market opens on Tuesday, July 31st. IRADIMED
management will host a conference call the same day beginning at
11:00 a.m. Eastern Time to discuss those results and to answer
questions.
Individuals interested in listening to the conference call may
do so by dialing 1-844-413-1781 for domestic callers, or
1-716-247-5767 for international callers, and entering reservation
code 2194419.
The conference call will also be available real-time via the
Internet at http://www.iradimed.com/en-us/investors/events/. A
recording of the call will be available on the Company’s website
for 90 days following completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of
innovative magnetic resonance imaging (“MRI”) compatible medical
devices. We are the only known provider of a non-magnetic
intravenous (“IV”) infusion pump system that is specifically
designed to be safe for use during MRI procedures. We were the
first to develop an infusion delivery system that largely
eliminates many of the dangers and problems present during MRI
procedures. Standard infusion pumps contain magnetic and electronic
components which can create radio frequency interference and are
dangerous to operate in the presence of the powerful magnet that
drives an MRI system. Our patented MRidium® MRI compatible IV
infusion pump system has been designed with a non-magnetic
ultrasonic motor, uniquely-designed non-ferrous parts and other
special features in order to safely and predictably deliver
anesthesia and other IV fluids during various MRI procedures. Our
pump solution provides a seamless approach that enables accurate,
safe and dependable fluid delivery before, during and after an MRI
scan, which is important to critically-ill patients who cannot be
removed from their vital medications, and children and infants who
must generally be sedated in order to remain immobile during an MRI
scan.
Our 3880 MRI compatible patient vital signs monitoring system
has been designed with non-magnetic components and other special
features in order to safely and accurately monitor a patient’s
vital signs during various MRI procedures. The iRadimed 3880 system
operates dependably in magnetic fields up to 30,000 gauss, which
means it can operate virtually anywhere in the MRI scanner room.
The iRadimed 3880 has a compact, lightweight design allowing it to
travel with the patient from their critical care unit, to the MRI
and back, resulting in increased patient safety through
uninterrupted vital signs monitoring and decreasing the amount of
time critically ill patients are away from critical care units. The
features of the iRadimed 3880 include: wireless ECG with dynamic
gradient filtering; wireless SpO2 using Masimo® algorithms;
non-magnetic respiratory CO2; non-invasive blood pressure; patient
temperature, and; optional advanced multi-gas anesthetic agent unit
featuring continuous Minimum Alveolar Concentration measurements.
The iRadimed 3880 MRI compatible patient vital signs monitoring
system has an easy-to-use design and allows for the effective
communication of patient vital signs information to clinicians.
For more information please visit www.iradimed.com.
Media Contact:Chris ScottChief Financial OfficerIRADIMED
CORPORATION(407) 677-8022 InvestorRelations@iradimed.com
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jul 2023 to Jul 2024